vs
Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and KKR Real Estate Finance Trust Inc. (KREF). Click either name above to swap in a different company.
KKR Real Estate Finance Trust Inc. is the larger business by last-quarter revenue ($25.8M vs $18.6M, roughly 1.4× ENANTA PHARMACEUTICALS INC). ENANTA PHARMACEUTICALS INC runs the higher net margin — -64.1% vs -101.7%, a 37.6% gap on every dollar of revenue. On growth, ENANTA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.8% vs -26.6%). Over the past eight quarters, ENANTA PHARMACEUTICALS INC's revenue compounded faster (4.5% CAGR vs -18.8%).
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
KKR Real Estate Finance Trust Inc. is a specialized real estate finance firm sponsored by global investment firm KKR. It primarily originates, acquires, and manages a portfolio of senior secured commercial real estate loans, mostly backed by high-quality institutional commercial properties across the United States, delivering stable risk-adjusted returns to investors via interest income from its diversified assets.
ENTA vs KREF — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $25.8M |
| Net Profit | $-11.9M | $-26.2M |
| Gross Margin | — | — |
| Operating Margin | -60.5% | -105.1% |
| Net Margin | -64.1% | -101.7% |
| Revenue YoY | 9.8% | -26.6% |
| Net Profit YoY | 46.4% | -229.6% |
| EPS (diluted) | $-0.42 | $-0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $25.8M | ||
| Q3 25 | $15.1M | $25.3M | ||
| Q2 25 | $18.3M | $30.2M | ||
| Q1 25 | $14.9M | $31.3M | ||
| Q4 24 | $17.0M | $35.1M | ||
| Q3 24 | $14.6M | $37.0M | ||
| Q2 24 | $18.0M | $40.4M | ||
| Q1 24 | $17.1M | $39.1M |
| Q4 25 | $-11.9M | $-26.2M | ||
| Q3 25 | $-18.7M | $13.8M | ||
| Q2 25 | $-18.3M | $-29.7M | ||
| Q1 25 | $-22.6M | $-4.9M | ||
| Q4 24 | $-22.3M | $20.3M | ||
| Q3 24 | $-28.8M | $-7.4M | ||
| Q2 24 | $-22.7M | $25.8M | ||
| Q1 24 | $-31.2M | $-3.1M |
| Q4 25 | -60.5% | -105.1% | ||
| Q3 25 | -121.6% | 50.4% | ||
| Q2 25 | -103.2% | -101.3% | ||
| Q1 25 | -164.3% | -18.3% | ||
| Q4 24 | -138.8% | 55.8% | ||
| Q3 24 | -204.4% | -19.6% | ||
| Q2 24 | -134.6% | 63.3% | ||
| Q1 24 | -192.1% | -8.7% |
| Q4 25 | -64.1% | -101.7% | ||
| Q3 25 | -123.6% | 54.4% | ||
| Q2 25 | -99.7% | -98.5% | ||
| Q1 25 | -151.7% | -15.5% | ||
| Q4 24 | -131.4% | 57.7% | ||
| Q3 24 | -197.3% | -20.0% | ||
| Q2 24 | -126.1% | 63.9% | ||
| Q1 24 | -182.7% | -7.9% |
| Q4 25 | $-0.42 | $-0.49 | ||
| Q3 25 | $-0.88 | $0.12 | ||
| Q2 25 | $-0.85 | $-0.53 | ||
| Q1 25 | $-1.06 | $-0.15 | ||
| Q4 24 | $-1.05 | $0.22 | ||
| Q3 24 | $-1.36 | $-0.19 | ||
| Q2 24 | $-1.07 | $0.29 | ||
| Q1 24 | $-1.47 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $84.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.6M | $1.2B |
| Total Assets | $329.5M | $6.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.4M | $84.6M | ||
| Q3 25 | $32.3M | $204.1M | ||
| Q2 25 | $44.8M | $107.7M | ||
| Q1 25 | $60.2M | $106.4M | ||
| Q4 24 | $84.3M | $104.9M | ||
| Q3 24 | $37.2M | $108.8M | ||
| Q2 24 | $35.8M | $107.2M | ||
| Q1 24 | $63.5M | $106.5M |
| Q4 25 | $126.6M | $1.2B | ||
| Q3 25 | $64.7M | $1.2B | ||
| Q2 25 | $79.3M | $1.2B | ||
| Q1 25 | $93.5M | $1.3B | ||
| Q4 24 | $111.8M | $1.3B | ||
| Q3 24 | $128.8M | $1.4B | ||
| Q2 24 | $148.9M | $1.4B | ||
| Q1 24 | $166.1M | $1.4B |
| Q4 25 | $329.5M | $6.5B | ||
| Q3 25 | $280.7M | $6.5B | ||
| Q2 25 | $301.0M | $6.8B | ||
| Q1 25 | $323.0M | $6.6B | ||
| Q4 24 | $348.6M | $6.4B | ||
| Q3 24 | $376.7M | $6.8B | ||
| Q2 24 | $398.8M | $7.1B | ||
| Q1 24 | $413.6M | $7.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $72.3M |
| Free Cash FlowOCF − Capex | $-11.8M | — |
| FCF MarginFCF / Revenue | -63.6% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-18.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.7M | $72.3M | ||
| Q3 25 | $-6.5M | $18.5M | ||
| Q2 25 | $17.5M | $21.1M | ||
| Q1 25 | $-13.5M | $15.9M | ||
| Q4 24 | $-16.8M | $132.6M | ||
| Q3 24 | $-10.4M | $49.1M | ||
| Q2 24 | $-14.8M | $30.6M | ||
| Q1 24 | $-28.6M | $34.5M |
| Q4 25 | $-11.8M | — | ||
| Q3 25 | $-7.9M | — | ||
| Q2 25 | $17.4M | — | ||
| Q1 25 | $-16.0M | — | ||
| Q4 24 | $-25.5M | — | ||
| Q3 24 | $-19.4M | — | ||
| Q2 24 | $-21.3M | — | ||
| Q1 24 | $-30.3M | — |
| Q4 25 | -63.6% | — | ||
| Q3 25 | -52.5% | — | ||
| Q2 25 | 94.7% | — | ||
| Q1 25 | -107.4% | — | ||
| Q4 24 | -150.6% | — | ||
| Q3 24 | -132.5% | — | ||
| Q2 24 | -118.6% | — | ||
| Q1 24 | -177.5% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 9.6% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 17.0% | — | ||
| Q4 24 | 51.6% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 36.4% | — | ||
| Q1 24 | 9.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.54× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.19× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
